Oral tramadol is a commonly prescribed analgesic in Hong Kong. Significant adverse effects are frequently observed in our locality. Our study aims to describe the rate of significant adverse effect that warrant discontinuation of oral tramadol and identify the risk factors for development of adverse effect.
Design
Retrospective cohort study.
Methods
Adult patients aged greater than 18 years old admitted to the emergency medicine ward of a large-scale local hospital in Hong Kong being prescribed with oral tramadol during in-hospital stay were recruited. Significant adverse effects during the hospital stay were observed as the outcome of interest.
Results
A total of 575 subjects were recruited. 29.9% experienced significant adverse effects likely related to tramadol. Age (p=0.006; odds ratio [OR] = 1.017, 95% confidence interval [CI] = 1.005-1.029) and sex (p=0.006; OR=1.696, 95% CI= 1.166-2.465) were statistically significant predictors of adverse effects after oral tramadol.
Conclusion
Our study suggests that female and increasing age patients are significant predictors for the development of adverse effect after taking oral tramadol. Possible adverse effects should be explained to the patients careful especially the higher risk groups. (Hong Kong j. emerg.med. 2014;21:3-9)
ArgoffC.E., SilversheinD.I.A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc2009; 84(7): 602–12.
4.
DhillonS.Tramadol/Paracetamol fixed-dose combination; a review of its use in the management of moderate to severe pain. Clinical Drug Investigation2010; 30(10): 711–38.
5.
MullicanW.S., LacyJ.R.Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial. Clin Ther2001; 23(9): 1429–45.
6.
HummelT., HummelC., FriedelI., PauliE., KobalG.A comparison of the antinociceptive effects of imipramine, tramadol and anpirtoline. Br J Clin Pharmacol1994; 37(4): 325–33.
ReigE.Tramadol in musculoskeletal pain – a survey. Clin Rheumatol2002; 21 Suppl 1: S9–12.
9.
NgK.F., TsuiS.L., YangJ.C., HoE.T.Comparison of tramadol and tramadol/droperidol mixture for patient-controlled analgesia. Can J Anaesth1997; 44(8): 810–5.
10.
XiaD.Y., WangY.H., GuoT., LiX.L., SuX.Y., ZhaoL.S.Pharmacokinetics of tramadol in a diverse healthy Chinese population. J Clin Pharm Ther2012; 37(5): 599–603.
11.
LeeH.K.H., LauF.L.A randomised control trial comparing the efficacy of tramadol and paracetamol against ketorolac and paracetamol in the management of musculoskeletal pain in the emergency department. Hong Kong J Emerg Med2008; 15(1): 5–11.
12.
SiuA.Y.C., ChungC.H.A pilot study on the use of tramadol hydrochloride for pain control in an emergency department. Hong Kong J Emerg Med2004; 11(1): 16–20.
13.
GrondS., SablotzkiA.Clinical pharmacology of tramadol. Clin Pharmacokinet2004; 43(13): 879–923.
FrinkM Ch, HenniesH.H., EnglbergerW., HaurandM., WilffertB.Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung1996; 46(11): 1029–36.
García-QuetglasE., AzanzaJ.R., SádabaB., MuñozM.J., GilI., CampaneroM.A.Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol Res2007; 55(2): 122–30.
18.
BamigbadeT.A., LangfordR.M.The clinical use of tramadol hydrochloride. Pain Reviews1998; 5: 155–82.
19.
McCarbergB.Tramadol extended-release in the management of chronic pain. Ther Clin Risk Manag2007; 3(3): 401–10.
20.
CloseB.R.Tramadol: does it have a role in emergency medicine?Emerg Med Australas2005; 17(1): 73–83.
KlotzU.Tramadol – the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung2003; 53(10): 681–7.
23.
SynderG.L., GreenbergS.Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth2010; 105(2): 106–15.
24.
PageG.G.Immunologic effects of opioids in the presence or absence of pain. J Pain Symptom Manage2005; 29(5 Suppl): S25–31.
25.
GandhiM., AweekaF., GreenblattR.M., BlaschkeT.F.Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol2004; 44: 499–523.
26.
CoskunT., SevincA., TevetogluI., AlicanI., KurtelH., YegenB.C.Delayed gastric emptying in conscious male rats following chronic estrogen and progesterone treatment. Res Exp Med (Berl)1995; 195(1): 49–54.
27.
MillerM.A.Gender-based differences in the toxicity of pharmaceuticals – The food and drug administration's perspective. Int J Toxicol2001; 20(3): 149–52.
28.
LamL.C., Garcia-BarceloM.M., UngvariG.S., TangW.K., LamV.K.Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry2001; 34(6): 238–41.
29.
KandoJ.C., YonkersK.A., ColeJ.O.Gender as risk factors for adverse events to medications. Drugs1995; 50(1): 1–6.
30.
RobertsS.B., DallalG.E.Energy requirements and aging. Public Health Nutr2005; 8(7A): 1028–36.
